Founded with a mission to innovate in the field of ophthalmic therapeutics, MingSight Pharmaceuticals is a clinical-stage company dedicated to improving the care of patients with serious eye diseases. The company focuses on the development of MS-553, a selective inhibitor of protein kinase C (PKC) beta, which aims to address the limitations of previous pan-PKC inhibitors. MingSight’s core vision is to leverage advanced biopharmaceutical research and clinical trials to bring effective treatments for conditions like chronic lymphocytic leukemia (CLL) and diabetic macular edema (DME).
Notable figures affiliated with MingSight Pharmaceuticals include experienced researchers and industry veterans who have significantly contributed to its strategic direction and scientific advancements. The company has garnered attention from key investors in the biopharmaceutical sector, supporting its innovative approach and clinical progress. Among its key achievements are promising proof-of-activity data from ongoing clinical studies, positioning MingSight as a potential leader in targeted ophthalmic therapies. The overall impact of MingSight Pharmaceuticals lies in its commitment to addressing unmet medical needs through cutting-edge research and development.
MingSight Pharmaceuticals' most recent funding round was for $20M (USD) in November 2021.
As of Nov 9, 2021, MingSight Pharmaceuticals has disclosed funding of $20M (USD).

MediPrint Ophthalmics
mediprintlens.com

PanOptica

EyeCyte
eyecyte.com

Lenz Therapeutics
lenz-tx.com

IACTA Pharmaceuticals

Visiox
visioxpharma.com

Phanes Therapeutics
phanesthera.com
MacuCLEAR

Mobius Therapeutics

Qlaris Bio
qlaris.bio

Ocumension Therapeutics

VIAN Therapeutics
viantx.com

Nacuity Pharmaceuticals
nacuity.com

Pathalys Pharma
pathalys.com

Zhaoke Ophthalmology Pharmaceutical
zkoph.com

Kiniksa Pharmaceuticals
kiniksa.com

Accelerated Vision Group

Imagen Biotech

EyePoint
eyepoint.bio

Surface Pharmaceuticals
surfacepharma.com